Boothbay Fund Management LLC Sells 133,415 Shares of Establishment Labs Holdings Inc. $ESTA

Boothbay Fund Management LLC decreased its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 30.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 299,291 shares of the company’s stock after selling 133,415 shares during the period. Establishment Labs comprises about 0.3% of Boothbay Fund Management LLC’s investment portfolio, making the stock its 13th biggest position. Boothbay Fund Management LLC owned 1.03% of Establishment Labs worth $21,812,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the stock. Kestra Advisory Services LLC bought a new position in shares of Establishment Labs during the 4th quarter valued at $47,000. Quarry LP bought a new position in shares of Establishment Labs during the 3rd quarter valued at $34,000. Osaic Holdings Inc. grew its holdings in shares of Establishment Labs by 900.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after purchasing an additional 1,800 shares during the last quarter. Truist Financial Corp bought a new position in shares of Establishment Labs during the 4th quarter valued at $200,000. Finally, Choreo LLC bought a new position in shares of Establishment Labs during the 4th quarter valued at $204,000. Institutional investors own 72.91% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ESTA. Needham & Company LLC increased their target price on shares of Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a report on Tuesday, February 24th. TD Cowen reaffirmed a “buy” rating on shares of Establishment Labs in a report on Monday, June 8th. BTIG Research increased their target price on shares of Establishment Labs from $88.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Canaccord Genuity Group increased their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Finally, Wall Street Zen lowered shares of Establishment Labs from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.14.

Insider Transactions at Establishment Labs

In other Establishment Labs news, Director Quiros Juan Jose Chacon sold 105,000 shares of the firm’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total value of $7,919,100.00. Following the sale, the director owned 927,504 shares of the company’s stock, valued at $69,952,351.68. This trade represents a 10.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders have sold 330,000 shares of company stock valued at $22,854,538. 9.99% of the stock is owned by company insiders.

Establishment Labs Price Performance

Shares of Establishment Labs stock opened at $82.39 on Thursday. The firm has a market cap of $2.42 billion, a PE ratio of -55.29 and a beta of 1.11. Establishment Labs Holdings Inc. has a 12-month low of $33.35 and a 12-month high of $86.00. The company has a quick ratio of 1.91, a current ratio of 2.96 and a debt-to-equity ratio of 16.82. The company’s fifty day simple moving average is $70.25 and its two-hundred day simple moving average is $69.48.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). The firm had revenue of $59.88 million during the quarter, compared to the consensus estimate of $57.40 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.Establishment Labs’s revenue was up 44.7% on a year-over-year basis. During the same period last year, the business earned ($0.70) EPS. As a group, equities analysts expect that Establishment Labs Holdings Inc. will post -1.07 EPS for the current year.

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.